In the last trading session, 2.82 million Dianthus Therapeutics Inc (NASDAQ:DNTH) shares changed hands as the company’s beta touched 1.56. With the company’s per share price at $21.97 changed hands at $0.64 or 3.00% during last session, the market valuation stood at $705.79M. DNTH’s last price was a discount, traded about -53.71% off its 52-week high of $33.77. The share price had its 52-week low at $18.13, which suggests the last value was 17.48% up since then. When we look at Dianthus Therapeutics Inc’s average trading volume, we note the 10-day average is 0.5 million shares, with the 3-month average coming to 237.86K.
Analysts gave the Dianthus Therapeutics Inc (DNTH) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended DNTH as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Dianthus Therapeutics Inc’s EPS for the current quarter is expected to be -0.71.
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Instantly DNTH was in green as seen at the end of in last trading. With action -9.74%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 0.78%, with the 5-day performance at -9.74% in the red. However, in the 30-day time frame, Dianthus Therapeutics Inc (NASDAQ:DNTH) is -8.95% down. Looking at the short shares, we see there were 5.42 million shares sold at short interest cover period of 25.81 days.
The consensus price target for the stock as assigned by Wall Street analysts is 52, meaning bulls need an upside of 57.75% from its current market value. According to analyst projections, DNTH’s forecast low is 52 with 52 as the target high. To hit the forecast high, the stock’s price needs a -136.69% plunge from its current level, while the stock would need to soar -136.69% for it to hit the projected low.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
Year-over-year growth is forecast to reach -43.62% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 806.9k. 10 analysts are of the opinion that Dianthus Therapeutics Inc’s revenue for the current quarter will be 910.7k. The company’s revenue for the corresponding quarters a year ago was 874k and 1.86M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -7.68%. The estimates for the next quarter sales put growth at -51.12%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 40.14%. The 2025 estimates are for Dianthus Therapeutics Inc earnings to decrease by -33.43%, but the outlook for the next 5-year period is at -16.78% per year.
DNTH Dividends
Dianthus Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-10.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.07% of Dianthus Therapeutics Inc shares while 110.61% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 120.31%. There are 110.61% institutions holding the Dianthus Therapeutics Inc stock share, with JANUS HENDERSON GROUP PLC the top institutional holder. As of 2024-06-30, the company held 1.9741% of the shares, roughly 0.68 million DNTH shares worth $17.56 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 0.7304% or 0.25 million shares worth $6.47 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . With 933.52 shares estimated at $20.51 million under it, the former controlled 3.15% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.65% of the shares, roughly 785.32 shares worth around $17.25 million.
